Definition and epidemiology
Pediatric dyslipidaemia is an abnormal lipid profile — most often elevated LDL cholesterol, elevated non-HDL cholesterol or triglycerides, or low HDL — that raises lifetime atherosclerotic cardiovascular risk. It is multifactorial (obesity, diet, inactivity, insulin resistance) in the majority, or monogenic, chiefly familial hypercholesterolaemia (FH), an autosomal dominant disorder affecting roughly 1 in 300 people, which is dangerously underdiagnosed. Atherosclerosis begins in childhood and lipid levels track into adulthood, which is the rationale for screening before symptoms appear. India’s rising childhood obesity and the South Asian predisposition to atherogenic dyslipidaemia (high triglycerides, low HDL) make this clinically relevant well beyond Western cohorts.
Clinical features
Dyslipidaemia is asymptomatic and detected on screening — there is no reliable physical sign in most children. Pointers to FH are a family history of early cardiovascular disease (men <55, women <65 years), familial hypercholesterolaemia, or markedly elevated LDL; tendon xanthomas and arcus are uncommon in childhood. Severe hypertriglyceridaemia can cause eruptive xanthomas and carries pancreatitis risk. Look for the metabolic context — obesity, acanthosis nigricans, hypertension — and secondary causes (hypothyroidism, nephrotic syndrome, diabetes, cholestasis, certain drugs).
Diagnosis
Per NHLBI/AAP guidance, universal screening is recommended once at ages 9–11 years and again at 17–21 years, with targeted screening earlier (from age 2) for children with a positive family history, FH, or risk factors such as obesity, diabetes or hypertension. A non-fasting non-HDL cholesterol (total cholesterol minus HDL) is an acceptable universal screen; abnormal results are confirmed on a fasting lipid profile. Widely used cutpoints: acceptable / borderline / high — total cholesterol <170 / 170–199 / ≥200 mg/dL; LDL <110 / 110–129 / ≥130 mg/dL; non-HDL <120 / 120–144 / ≥145 mg/dL; HDL low <40 mg/dL; triglycerides (0–9 y) ≥100 and (10–19 y) ≥130 mg/dL considered high. Persistent LDL ≥160 mg/dL (or ≥130 with family history) raises concern for FH. Always exclude secondary causes before labelling primary dyslipidaemia.
See the full criteria: Dyslipidemia
Red flags
- LDL persistently ≥190 mg/dL, or ≥160 mg/dL with a family history — probable familial hypercholesterolaemia
- Family history of premature cardiovascular disease (men <55, women <65 years)
- Triglycerides ≥500 mg/dL — pancreatitis risk, needs urgent attention
- Eruptive xanthomas or tendon xanthomas
- Dyslipidaemia with hypertension, type 2 diabetes or obesity — clustered cardiometabolic risk
Management overview
First-line for nearly all children is lifestyle and diet — a heart-healthy eating pattern (reduced saturated/trans fat and added sugar, more fibre, fruit and vegetables), increased physical activity, weight management and tobacco-smoke avoidance — reassessed after a structured trial (typically several months). Treat secondary causes on their own merits. Pharmacotherapy (statins are the usual first agent) is reserved for children, generally from about age 10, with persistently high LDL despite lifestyle measures or with FH/high-risk conditions, and is a specialist-supported decision — no doses are given here. Severe hypertriglyceridaemia needs dietary fat restriction and specialist input to avert pancreatitis. Refer suspected FH for confirmation, cascade family screening and management. In the Indian context, screen the broader family when FH is found and address the common low-HDL/high-triglyceride pattern within overall cardiometabolic care.
References
- NHLBI Expert Panel. Pediatrics. 2011;128(Suppl 5):S213–S256 (integrated cardiovascular guidelines).
- de Ferranti SD, et al. AAP lipid screening and management updates.
- Pediatric Dyslipidemia, StatPearls; Endotext — Dyslipidemia in Children and Adolescents.
Decision support for qualified clinicians only — verify against current primary guidelines and your clinical judgement.